M. Manns, J. Mchutchison, and S. Gordon, Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial, The Lancet, vol.358, issue.9286, pp.958-965, 2001.
DOI : 10.1016/S0140-6736(01)06102-5

D. Franceschi, L. Fattovich, G. Turrini, and F. , Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus Editorial pm Š ce infection: role of membrane oxidative damage, Hepatology, vol.5, issue.31, pp.58997-1004, 2000.

J. Mchutchison, M. Manns, and K. Patel, Adherence to combination therapy enhances sustained response in genotype-1???infected patients with chronic hepatitis C, Gastroenterology, vol.123, issue.4, pp.1061-1069, 2002.
DOI : 10.1053/gast.2002.35950

J. Jen, P. Glue, and S. Gupta, Population Pharmacokinetic and Pharmacodynamic Analysis of Ribavirin in Patients With Chronic Hepatitis C, Therapeutic Drug Monitoring, vol.22, issue.5, pp.555-565, 2000.
DOI : 10.1097/00007691-200010000-00010

J. Mchutchison, E. Lawitz, and M. Shiffman, Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection, New England Journal of Medicine, vol.361, issue.6, pp.580-593, 2009.
DOI : 10.1056/NEJMoa0808010

M. Sulkowski, M. Shiffman, and N. Afdhal, Hepatitis C Virus Treatment-Related Anemia Is Associated With Higher Sustained Virologic Response Rate, Gastroenterology, vol.139, issue.5, pp.1602-1611, 2010.
DOI : 10.1053/j.gastro.2010.07.059

N. Afdhal, Role of epoetin alfa in maintaining ribavirin dose, Gastroenterology Clinics of North America, vol.33, issue.1, pp.25-35, 2004.
DOI : 10.1016/j.gtc.2003.12.002

D. Dieterich, R. Wasserman, and N. Brau, Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa, Am J Gastroenterol, vol.98, pp.2491-2499, 2003.

D. Moradpour, F. Penin, and C. Rice, Replication of hepatitis C virus, Nature Reviews Microbiology, vol.281, issue.6, pp.453-463, 2007.
DOI : 10.1038/nrmicro1645

URL : https://hal.archives-ouvertes.fr/hal-00313684

I. Jacobson, J. Mchutchison, and G. Dusheiko, Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection, New England Journal of Medicine, vol.364, issue.25, pp.2405-2416, 2011.
DOI : 10.1056/NEJMoa1012912

F. Poordard, J. Mccone, and B. Bacon, Boceprevir for Untreated Chronic HCV Genotype 1 Infection, New England Journal of Medicine, vol.364, issue.13, pp.1195-1206, 2011.
DOI : 10.1056/NEJMoa1010494

B. Bacon, S. Gordon, and E. Lawitz, Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection, New England Journal of Medicine, vol.364, issue.13, pp.1207-1217, 2011.
DOI : 10.1056/NEJMoa1009482

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3153125

S. Zeuzem, P. Andreone, and S. Pol, Telaprevir for Retreatment of HCV Infection, New England Journal of Medicine, vol.364, issue.25, pp.2417-2428, 2011.
DOI : 10.1056/NEJMoa1013086

D. Burger, D. Back, and P. Buggish, Clinical management of drug???drug interactions in HCV therapy: Challenges and solutions, Journal of Hepatology, vol.58, issue.4, pp.792-800, 2012.
DOI : 10.1016/j.jhep.2012.10.027

P. Cacoub, M. Bourlière, and J. Lübbe, Dermatological side effects of hepatitis C and its treatment: Patient management in the era of direct-acting antivirals, Journal of Hepatology, vol.56, issue.2, pp.455-463, 2012.
DOI : 10.1016/j.jhep.2011.08.006

C. Hézode, H. Fontaine, and C. Dorival, Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) ??? NCT01514890, Journal of Hepatology, vol.59, issue.3, pp.434-441, 2013.
DOI : 10.1016/j.jhep.2013.04.035

M. Sulkowski, K. Reddy, and N. Afdhal, 477 ANEMIA HAD NO EFFECT ON EFFICACY OUTCOMES IN TREATMENT-NAIVE PATIENTS WHO RECEIVED TELAPREVIR-BASED REGIMEN IN THE ADVANCE AND ILLUMINATE PHASE 3 STUDIES, Journal of Hepatology, vol.54, p.195, 2011.
DOI : 10.1016/S0168-8278(11)60479-0

F. Poordard, E. Lawitz, and K. Reddy, Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic HCV genotype 1 infection?a randomized trial, Gastroenterology, vol.XX, p.XXX?XXX, 2013.

V. Leroy, L. Serfaty, and M. Bourlière, Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver, Liver International, vol.56, issue.17, pp.1477-1492, 2012.
DOI : 10.1111/j.1478-3231.2012.02856.x

S. Acknowledgments, D. Pol, and . Matthew, Albert for his help in the preparation of the manuscript Conflicts of interest S. Pol has received consulting and lecturing fees from Bristol-Myers Squibb, p.0